profit from every $100 of sales.
$0$100
Alcon
$72.46-2.16% today
-6.3% in 1 year
1-year low $62.021-year high $87.18
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $35.74 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Alcon sold, what it kept, and what it did with the cash.
Sales went from $8.72 billion in 2022 to $10.4 billion in 2025, with $980 million of profit last year.
SalesProfit
Alcon handed back 52% of the cash it generated last year.
Buybacks $676M
Free cash flow 2025$1.6B
Bought back its own shares$676M
Paid as dividends$166M
Alcon vs. similar companies
Alcon grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Alcon | 35.7× · Expensive | ||
 Intuitive Surgical | 54.6× · Expensive | ||
 EssilorLuxottica Société anonyme | 36.1× · Expensive | ||
 Becton, Dickinson and | 34.8× · Expensive | ||
 Medline | 47.9× · Expensive |
AI analysis
An AI analyst reads Alcon's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 8,717 | 9,455 | 9,911 | 10,401 | |
| 4,748 | 5,247 | 5,512 | 5,745 | |
| 672 | 1,039 | 1,413 | 1,360 | |
| 1,720 | 2,242 | 2,676 | 2,699 | |
| 335 | 974 | 1,018 | 980 | |
| 0.68 | 1.96 | 2.05 | 1.98 | |
| 54.5% | 55.5% | 55.6% | 55.2% | |
| 7.7% | 11.0% | 14.3% | 13.1% | |
| 3.8% | 10.3% | 10.3% | 9.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 29,165 | 29,614 | 30,347 | 31,555 |
| Cash | 980 | 1,094 | 1,676 | – |
| Total debt | 5,068 | 5,135 | 497 | 509 |
| Total liabilities | 9,488 | 8,990 | 30,347 | 31,555 |
| 19,677 | 20,624 | 21,533 | 22,014 | |
| 494 | 497 | 498 | 496 | |
| 1.9% | 3.1% | 5.2% | 4.8% | |
| 1.7% | 4.7% | 4.7% | 4.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,217 | 1,388 | 2,077 | 2,271 | |
| 745 | 851 | 670 | 663 | |
| 472 | 537 | 1,407 | 1,608 | |
| Dividends paid | 100 | 116 | 130 | 166 |
| – | 0 | 0 | 676 | |
| 140 | 144 | 150 | 162 |
Valuation
- 35.7×
- 21.1×
- 0.84
- 1.6×
- 3.4×
- 21.8×
- 13.2×
- 4.6%
- 2.8%
- 0.6%
Profitability
- 55.2%
- 13.1%
- 9.4%
- 18.3%
- 4.1%
- 3.4%
- 4.4%
- 3.1%
- 4.8%
- 9.5%
Growth
- +6.1%
- +42.8%
- +22.8%
- –
- +0.1%
Financial health
- 1.4×
- 0.24
- 16.6%
- 6.7×
- 2.12
- 1.33
- 0.33
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 44%of 958
Top 40%of 889
Bottom 35%of 601
Bottom 33%of 890
Top 25%of 987
What analysts expect
- Average price target
- $93.36
- Range
- $82.00 – $101.09
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.85 | 0.80 | +6.2% |
| Feb 24, 2026 | 0.78 | 0.79 | −1.3% |
| Nov 11, 2025 | 0.79 | 0.77 | +2.6% |
| Aug 19, 2025 | 0.76 | 0.71 | +7.0% |
| May 13, 2025 | 0.73 | 0.76 | −3.9% |
| Feb 25, 2025 | 0.72 | 0.70 | +2.9% |
| Nov 12, 2024 | 0.81 | 0.72 | +12.5% |
| Aug 20, 2024 | 0.74 | 0.74 | +0.0% |
0.6%of the share price, paid each year
On $1,000 invested$6a year at today's yield, before tax
–per share
Raised4 yearsin a row, in our data
Paid per share, each year
$0.11 in 2021 → $0.33 in 2025
How safe it looks
16.9% of its profit
Room to growStretchedMore than it earns: 10.3%
News
Earnings Week Ahead: CSCO, CRWV, PLUG, ALC, AMAT, ACB, RKLB, ASTS, and moreSeeking Alpha · Nov 8, 2026Alcon wins approval of OTC Brytly eye dropsSeeking Alpha · Oct 16, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
57No pass
Philip Fisher
60Pass
Peter Lynch
79Pass
Joel Greenblatt
10No pass
Charlie Munger
43No pass
Terry Smith
46No pass
Questions about Alcon
Is Alcon a good stock to buy?
A solid business, but the price is high. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Alcon AI analysis
What does Alcon do?
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It is in Medical Instruments & Supplies, based in Geneva, Switzerland, with 25,000 employees.
Does Alcon pay a dividend?
Yes. At today's price the dividend is 0.6% a year, about 17% of its yearly profit. In 2025 it paid out $166 million in dividends.
Is Alcon stock halal?
Yes. Alcon passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Alcon stock done over the past year?
Down 6.3% over the past twelve months, to $72.46. It traded between $62.02 and $87.18 and is 16.9% below its high.
Who are Alcon's competitors?
The largest listed companies in the same industry are Intuitive Surgical, EssilorLuxottica Société anonyme, Becton, Dickinson and and Medline. The peers table on this page compares their profit, growth and price with Alcon's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.